This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Van Driessche A, Berneman ZN, Van Tendeloo VF . Active specific immunotherapy targeting the Wilms’ tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012; 17: 250–259.
Anguille S, Van Tendeloo VF, Berneman ZN . Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; e-pub ahead of print 6 July 2012; doi:10.1038/leu.2012.145.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.
Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.
Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al. A clinicaland immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541–6548.
Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824–13829.
Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012; 26: 1410–1413.
Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VFI . Dendritic cell vaccine therapy for acute myeloid leukemia Questions and answers. Hum Vaccines 2011; 7: 579–584.
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA et al. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells. Microbiol Immunol 2008; 52: 591–600.
Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR . Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: D913–D919.
Williams F, Meenagh A, Single R, McNally M, Kelly P, Nelson MP et al. High resolution HLA-DRB1 identification of a caucasian population. Hum Immunol 2004; 65: 66–77.
Chattopadhyay PK, Yu J, Roederer M . A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005; 11: 1113–1117.
Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G et al. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res 2009; 15: 4467–4474.
Faner R, James E, Huston L, Pujol-Borrel R, Kwok WW, Juan M . Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation. Eur J Immunol 2010; 40: 91–102.
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N et al. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 2010; 30: 2247–2254.
Acknowledgements
This work was made possible by funding from the Belgian National Cancer Plan (initiative 29), the Research Foundation–Flanders (FWO), the Belgian Foundation against Cancer and the Belgian public utility foundation VOCATIO. SA is a former PhD fellow of FWO and currently holds an Emmanuel van der Schueren Fellowship of the Flemish League against Cancer. ES is a postdoctoral researcher granted by FWO. This study was also supported, in part, by a Grant-in-Aid for Young Scientists (WAKATE B-22700896) from the Ministry of Education, Science, Sports, Culture and Technology, and the Ministry of Health, Labor and Welfare of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Anguille, S., Fujiki, F., Smits, E. et al. Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes. Leukemia 27, 748–750 (2013). https://doi.org/10.1038/leu.2012.248
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.248
This article is cited by
-
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides
Cancer Immunology, Immunotherapy (2021)